Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Dose-Ranging Study of INCB054707 in Hidradenitis Suppurativa
2020-001981-13Phase 2Completed
- Sponsor
- Incyte
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of povorcitinib in hidradenitis suppurativa (HS) (4 arms), sponsored by Incyte. Primary endpoint: Mean change in abscess and inflammatory nodule count at Week 16. Started Sep 2021; status: completed.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2020-001981-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001981-13.